JP2009502829A5 - - Google Patents

Download PDF

Info

Publication number
JP2009502829A5
JP2009502829A5 JP2008523188A JP2008523188A JP2009502829A5 JP 2009502829 A5 JP2009502829 A5 JP 2009502829A5 JP 2008523188 A JP2008523188 A JP 2008523188A JP 2008523188 A JP2008523188 A JP 2008523188A JP 2009502829 A5 JP2009502829 A5 JP 2009502829A5
Authority
JP
Japan
Prior art keywords
alkylene
alkyl
halogen
aryl
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008523188A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009502829A (ja
JP5060478B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2006/007139 external-priority patent/WO2007012421A1/en
Publication of JP2009502829A publication Critical patent/JP2009502829A/ja
Publication of JP2009502829A5 publication Critical patent/JP2009502829A5/ja
Application granted granted Critical
Publication of JP5060478B2 publication Critical patent/JP5060478B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008523188A 2005-07-26 2006-07-20 Rho−キナーゼ阻害剤としてのピペリジニル置換されたイソキノロン誘導体 Active JP5060478B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05016154 2005-07-26
EP05016154.6 2005-07-26
PCT/EP2006/007139 WO2007012421A1 (en) 2005-07-26 2006-07-20 Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2009502829A JP2009502829A (ja) 2009-01-29
JP2009502829A5 true JP2009502829A5 (enExample) 2009-09-03
JP5060478B2 JP5060478B2 (ja) 2012-10-31

Family

ID=34979095

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008523188A Active JP5060478B2 (ja) 2005-07-26 2006-07-20 Rho−キナーゼ阻害剤としてのピペリジニル置換されたイソキノロン誘導体

Country Status (31)

Country Link
US (1) US8188117B2 (enExample)
EP (2) EP2385047B1 (enExample)
JP (1) JP5060478B2 (enExample)
KR (1) KR101373535B1 (enExample)
CN (1) CN101228149B (enExample)
AR (1) AR054868A1 (enExample)
AU (1) AU2006274245B2 (enExample)
BR (1) BRPI0613861B8 (enExample)
CA (1) CA2615577C (enExample)
CR (1) CR9603A (enExample)
DK (1) DK1910333T3 (enExample)
DO (1) DOP2006000178A (enExample)
EC (1) ECSP088135A (enExample)
ES (1) ES2423006T3 (enExample)
GT (1) GT200600328A (enExample)
IL (1) IL188702A (enExample)
MA (1) MA29636B1 (enExample)
MX (1) MX2008001053A (enExample)
MY (1) MY148479A (enExample)
NI (1) NI200800025A (enExample)
NO (1) NO341888B1 (enExample)
NZ (1) NZ565668A (enExample)
PE (1) PE20070217A1 (enExample)
PT (1) PT1910333E (enExample)
RU (1) RU2414467C2 (enExample)
TN (1) TNSN08039A1 (enExample)
TW (1) TWI383979B (enExample)
UA (1) UA93882C2 (enExample)
UY (1) UY29697A1 (enExample)
WO (1) WO2007012421A1 (enExample)
ZA (1) ZA200710951B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ565040A (en) 2005-06-28 2010-05-28 Sanofi Aventis Isoquinoline derivatives as inhibitors of RHO-kinase
RS52241B (sr) 2005-07-26 2012-10-31 Sanofi Derivati cikloheksilamin izohinolona kao inhibitori rho-kinaze
TW200738682A (en) * 2005-12-08 2007-10-16 Organon Nv Isoquinoline derivatives
CA2663193A1 (en) * 2006-09-11 2008-03-20 N.V. Organon 2-(1-oxo-1h-isoquinolin-2-yl)acetamide derivatives
WO2008077556A1 (en) 2006-12-27 2008-07-03 Sanofi-Aventis Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives
BRPI0721180A2 (pt) 2006-12-27 2014-03-18 Sanofi Aventis Derivados de isoquinolina substituídos com cicloalquilamina
NZ577981A (en) 2006-12-27 2011-12-22 Sanofi Aventis Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase
EP2114920A1 (en) 2006-12-27 2009-11-11 Sanofi-Aventis Substituted isoquinoline and isoquinolinone derivatives
EP2125745B1 (en) 2006-12-27 2017-02-22 Sanofi Cycloalkylamine substituted isoquinolone derivatives
MX2009005862A (es) 2006-12-27 2009-06-17 Sanofi Aventis Nuevos derivados de isoquinolina e isoquinolinona sustituidos.
CN103432133B (zh) * 2007-01-22 2016-08-10 Gtx公司 核受体结合剂的用途
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
JP2011507921A (ja) * 2007-12-26 2011-03-10 サノフィ−アベンティス 6−置換−1−(2h)−イソキノリノンの製造法
CA2728137C (en) 2008-06-24 2016-10-18 Sanofi-Aventis Substituted isoquinolines and isoquinolinones as rho kinase inhibitors
CA2728128C (en) 2008-06-24 2016-06-07 Sanofi-Aventis 6-substituted isoquinolines and isoquinolinones
CA2728123C (en) 2008-06-24 2017-02-21 Sanofi-Aventis Bi- and polycyclic substituted isoquinoline and isoquinolinone derivatives
US9865233B2 (en) 2008-12-30 2018-01-09 Intel Corporation Hybrid graphics display power management
EP2488520B1 (en) * 2009-10-13 2015-09-02 Merck Sharp & Dohme B.V. Condensed azine-derivatives for the treatment of diseases related to the acetylcholine receptor
EP2729007A1 (de) * 2011-07-04 2014-05-14 Bayer Intellectual Property GmbH Verwendung substituierter isochinolinone, isochinolindione, isochinolintrione und dihydroisochinolinone oder jeweils deren salze als wirkstoffe gegen abiotischen pflanzenstress
KR101959711B1 (ko) 2011-07-08 2019-03-19 사노피 치환된 페닐 화합물
CN103781778B (zh) * 2011-07-08 2015-10-07 赛诺菲 6-(哌啶-4-基氧基)-2h-异喹啉-1-酮盐酸盐的结晶性溶剂化物
EP2729461B1 (en) * 2011-07-08 2016-01-20 Sanofi Polymorphs of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride
EP3141235A1 (en) 2012-12-06 2017-03-15 IP Gesellschaft für Management mbH N-(6-((2r,3s)-3,4-dihydroxybutan-2-yloxy)-2-(4-fluorobenzylthio)pyrimidin-4-yl)-3-methylazetidine-l -sulfonamide
LT3057586T (lt) 2013-10-18 2020-03-10 Celgene Quanticel Research, Inc. Bromodomeno inhibitoriai
RS61519B1 (sr) 2013-11-18 2021-03-31 Forma Therapeutics Inc Sastavi tetrahidrohinolina kao inhibitori bet bromodomena
FR3017868A1 (fr) 2014-02-21 2015-08-28 Servier Lab Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP3237397B1 (en) 2014-12-24 2018-11-21 Gilead Sciences, Inc. Isoquinoline compounds for the treatment of hiv
AU2015371255B2 (en) 2014-12-24 2018-09-27 Gilead Sciences, Inc. Fused pyrimidine compounds for the treatment of HIV
TW202237569A (zh) 2014-12-24 2022-10-01 美商基利科學股份有限公司 喹唑啉化合物
AR104259A1 (es) 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
HK1255034A1 (zh) 2015-07-01 2019-08-02 Crinetics Pharmaceuticals, Inc. 生长抑素调节剂及其用途
WO2017174879A1 (en) * 2016-04-06 2017-10-12 University Of Oulu Compounds for use in the treatment of cancer
AU2017252276A1 (en) 2016-04-18 2018-11-15 Celgene Quanticel Research, Inc. Therapeutic compounds
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
CN106632258B (zh) * 2016-12-15 2019-04-02 三峡大学 四氢异喹啉-2-基芳氧基苯氧基烷基酮化合物及其应用
EP3658560A4 (en) 2017-07-25 2021-01-06 Crinetics Pharmaceuticals, Inc. SOMATOSTAT IN MODULATORS AND USES THEREOF
CA3236332A1 (en) 2021-10-30 2023-05-04 Ziev B. Moses Treatments for disturbed cerebral homeostasis
JP2025525162A (ja) * 2022-08-01 2025-08-01 ヴァロ ヘルス インコーポレイテッド 6-置換-1-(2h)-イソキノリノン及び中間体化合物の製造方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2485537B2 (fr) 1977-04-13 1986-05-16 Anvar Dipyrido(4,3-b)(3,4-f)indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant
JPH06501921A (ja) 1990-07-31 1994-03-03 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 選択されたハロカーボンの触媒平衡化
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9516709D0 (en) 1995-08-15 1995-10-18 Zeneca Ltd Medicament
WO1997009311A1 (de) * 1995-09-07 1997-03-13 F. Hoffmann-La Roche Ag Neue 4-(oxyalkoxyphenyl)-3-oxy-piperidine zur behandlung von herz- und niereninsuffizienz
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
JP3669711B2 (ja) 1996-08-12 2005-07-13 三菱ウェルファーマ株式会社 Rhoキナーゼ阻害剤を含有する医薬
JPH1087629A (ja) 1996-09-18 1998-04-07 Fujisawa Pharmaceut Co Ltd 新規イソキノリン誘導体、およびその医薬用途
WO1999011642A1 (en) 1997-08-29 1999-03-11 Zeneca Limited Aminometyl oxooxazolidinyl benzene derivatives
TW575567B (en) 1998-10-23 2004-02-11 Akzo Nobel Nv Serine protease inhibitor
GB9912701D0 (en) 1999-06-01 1999-08-04 Smithkline Beecham Plc Novel compounds
US6541456B1 (en) 1999-12-01 2003-04-01 Isis Pharmaceuticals, Inc. Antimicrobial 2-deoxystreptamine compounds
IL150650A0 (en) 2000-01-20 2003-02-12 Eisai Co Ltd Piperidine derivatives and pharmaceutical compositions containing the same
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
US20040171533A1 (en) 2000-02-29 2004-09-02 Barbara Zehentner Methods and compositions for regulating adiopocytes
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
GB0013060D0 (en) 2000-05-31 2000-07-19 Astrazeneca Ab Chemical compounds
AU2001296008A1 (en) 2000-10-27 2002-05-06 Takeda Chemical Industries Ltd. Process for preparing substituted aromatic compounds and intermediates therefor
JP2004520347A (ja) 2001-01-15 2004-07-08 グラクソ グループ リミテッド Ldl−受容体発現のインデューサーとしてのアリールピペリジンおよびピペラジン誘導体
SE0101038D0 (sv) 2001-03-23 2001-03-23 Astrazeneca Ab Novel compounds
WO2002088101A2 (en) 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Inhibitors of bace
JPWO2002100833A1 (ja) * 2001-06-12 2004-09-24 住友製薬株式会社 Rhoキナーゼ阻害剤
GB0117899D0 (en) 2001-07-23 2001-09-12 Astrazeneca Ab Chemical compounds
WO2003024450A1 (en) 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating prion diseases
SE0104340D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New compounds
JPWO2004009555A1 (ja) * 2002-07-22 2005-11-17 旭化成ファーマ株式会社 5−置換イソキノリン誘導体
CA2502583A1 (en) 2002-09-12 2004-03-25 Kirin Beer Kabushiki Kaisha Isoquinoline derivatives having kinase inhibitory activity and medicament containing the same
US20050014783A1 (en) 2003-05-29 2005-01-20 Schering Aktiengesellschaft Use of Rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
EP1638939A2 (en) 2003-06-24 2006-03-29 Neurosearch A/S Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
CA2539479C (en) 2003-09-23 2010-07-06 Merck & Co., Inc. Isoquinoline potassium channel inhibitors
CA2539814C (en) 2003-09-23 2010-07-06 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
US20050067037A1 (en) 2003-09-30 2005-03-31 Conocophillips Company Collapse resistant composite riser
WO2005035516A1 (ja) 2003-10-10 2005-04-21 Ono Pharmaceutical Co., Ltd. 新規縮合複素環化合物およびその用途
JP2007008816A (ja) * 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
US7449477B2 (en) 2003-11-25 2008-11-11 Eli Lilly And Company 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B)
WO2005074535A2 (en) 2004-01-30 2005-08-18 Eisai Co., Ltd. Cholinesterase inhibitors for spinal cord disorders
WO2005087226A1 (en) 2004-03-05 2005-09-22 Eisai Co., Ltd. Cadasil treatment with cholinesterase inhibitors
SE0400850D0 (sv) 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
RS52241B (sr) 2005-07-26 2012-10-31 Sanofi Derivati cikloheksilamin izohinolona kao inhibitori rho-kinaze
TW200745101A (en) 2005-09-30 2007-12-16 Organon Nv 9-Azabicyclo[3.3.1]nonane derivatives
US7618985B2 (en) 2005-12-08 2009-11-17 N.V. Organon Isoquinoline derivatives
TW200738682A (en) * 2005-12-08 2007-10-16 Organon Nv Isoquinoline derivatives
US7893088B2 (en) 2006-08-18 2011-02-22 N.V. Organon 6-substituted isoquinoline derivatives
MX2009005862A (es) 2006-12-27 2009-06-17 Sanofi Aventis Nuevos derivados de isoquinolina e isoquinolinona sustituidos.
WO2008077556A1 (en) 2006-12-27 2008-07-03 Sanofi-Aventis Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives

Similar Documents

Publication Publication Date Title
JP2009502829A5 (enExample)
JP2009502830A5 (enExample)
RU2008106950A (ru) Пиперидинилзамещенные производные изохинолона как ингибиторы rho-киназы
RU2008106926A (ru) Производные циклогексиламинизохинолона в качестве ингибиторов rho-киназы
RU2009128645A (ru) Замещенные изохинолиновые и изохинолиноновые производные в качестве ингибиторов rho-киназы
RU2008102968A (ru) Производные изохинолина в качестве ингибиторов rho-киназы
RU2013104459A (ru) Карбоксамидные соединения и их применение в качестве ингибиторов кальпаинов
JP2010511626A5 (enExample)
RU2009128690A (ru) Новые замещенные производные изохинолина и изохинолинона
JP2008510691A5 (enExample)
ES2567630T3 (es) Derivados de tetrahidroindol como inhibidores de la NADPH oxidasa
JP2009529540A5 (enExample)
JP2014511891A5 (enExample)
JP2007502804A5 (enExample)
JP2019518766A5 (enExample)
JP2014511892A5 (enExample)
WO2006023460A3 (en) COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
JP2005505506A5 (enExample)
JP2006151984A5 (enExample)
RU2016144329A (ru) Агонисты рецептора апелина (apj) и его применение
RU2012132429A (ru) Бета-карболины для лечения нарушения слуха и головокружения
JP2008526999A5 (enExample)
JP2008510828A5 (enExample)
JP2005516967A5 (enExample)
JP2012526082A5 (enExample)